TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17113426

Group type: EXPERIMENTAL
Intervention: Etoricoxib (60 mg or 90 mg daily)
Number of subjects: 34701

Group type: COMPARATOR
Intervention: Diclofenac (150 mg daily)
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 34701

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 34701
Study: 17116834

Group type: EXPERIMENTAL
Intervention: Imiquimod treatment (self-applied cream or suppositories, 3 times a week for 16 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Imiquimod treatment
Number of subjects: 28
Study: 17130304

Group type: EXPERIMENTAL
Intervention: N(G)-Monomethyl-l-arginine (250 microg/kg per minute IV) during autonomic blockade
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: N(G)-Monomethyl-l-arginine (250 microg/kg per minute IV) in intact subjects
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Selective eNO blockade in normotensive smokers
Number of subjects: 33

Group type: COMPARATOR
Intervention: Selective eNO blockade in normotensive individuals
Number of subjects: 33
Study: 17133154

Group type: EXPERIMENTAL
Intervention: Levofloxacin (10 mg/kg twice a day for 10 days)
Number of subjects: 204
Study: 17161253

Group type: EXPERIMENTAL
Intervention: Total Cholesterol (TC)
Number of subjects: 15632

Group type: EXPERIMENTAL
Intervention: Low-Density Lipoprotein Cholesterol (LDL-C)
Number of subjects: 15632

Group type: EXPERIMENTAL
Intervention: High-Density Lipoprotein Cholesterol (HDL-C)
Number of subjects: 15632

Group type: EXPERIMENTAL
Intervention: Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
Number of subjects: 15632

Group type: EXPERIMENTAL
Intervention: High-Sensitivity C-Reactive Protein (hs-CRP)
Number of subjects: 15632

Group type: EXPERIMENTAL
Intervention: Total Cholesterol to High-Density Lipoprotein Cholesterol (TC to HDL-C) ratio
Number of subjects: 15632
Study: 17164793

Group type: EXPERIMENTAL
Intervention: Oncoretroviral-mediated ex vivo gene transfer in FA-A cells
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Re-infusion of gene-corrected products
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stem cell collection
Number of subjects: 2
Study: 17167135

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 47
Study: 17174643

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 5791

Group type: EXPERIMENTAL
Intervention: Other evidence-based beta blockers
Number of subjects: 5791
Study: 17183730

Group type: EXPERIMENTAL
Intervention: Hydralazine (182 mg for rapid-acetylators, 83 mg for slow-acetylators) and magnesium valproate (30 mg/kg) added to neoadjuvant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every 21 days.
Number of subjects: 16
Study: 17227587

Group type: EXPERIMENTAL
Intervention: StO2 measurement using NIRS in group A (without severe sepsis/septic shock)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: StO2 measurement using NIRS in group B (with severe sepsis/septic shock)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: StO2 measurement in group A
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Changes in StO2 in group A
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Plasma lactate concentrations in group A
Number of subjects: 65
Study: 17233910

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow derived mononuclear cell therapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (saline with 5% autologous serum)
Number of subjects: 300
Study: 17241734

Group type: EXPERIMENTAL
Intervention: Manual defibrillation
Number of subjects: 1165

Group type: COMPARATOR
Intervention: Semi-automatic defibrillation (AED)
Number of subjects: 1165
Study: 17242628

Group type: EXPERIMENTAL
Intervention: Atomoxetine (up to 1.8 mg/kg/day)
Number of subjects: 0
Study: 17251666

Group type: EXPERIMENTAL
Intervention: TACT protocol using bone marrow-mononuclear cells (MNCs) and peripheral blood-MNCs
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: TACT protocol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 7
Study: 17258088

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES) in patients with unstable angina (UA)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) in patients with stable angina (SA)
Number of subjects: 607
Study: 17263626

Group type: EXPERIMENTAL
Intervention: Interferon/ribavirin therapy
Number of subjects: 91
Study: 17276184

Group type: EXPERIMENTAL
Intervention: Higher log-CRP concentration in men
Number of subjects: 1164
Study: 17278106

Group type: EXPERIMENTAL
Intervention: ATLL cells from a subset of patients
Number of subjects: 0
Study: 17296644

Group type: EXPERIMENTAL
Intervention: Sputum induction during exacerbation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sputum induction during stable phase
Number of subjects: 44
Study: 17296825

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 1748

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (in patients with diabetes)
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Bare-metal stents (in patients with diabetes)
Number of subjects: 1748

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1748
Study: 17310025

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 27937

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol (LDL-C)
Number of subjects: 27937

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C)
Number of subjects: 27937

Group type: EXPERIMENTAL
Intervention: Total cholesterol to HDL-C ratio
Number of subjects: 27937

Group type: EXPERIMENTAL
Intervention: Non-HDL-C
Number of subjects: 27937
Study: 17325261

Group type: EXPERIMENTAL
Intervention: Telemedicine case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 17329707

Group type: EXPERIMENTAL
Intervention: Anemia correction intervention
Number of subjects: 0
Study: 17332146

Group type: EXPERIMENTAL
Intervention: Homocysteine
Number of subjects: 24968

Group type: EXPERIMENTAL
Intervention: MTHFR genotype (TT vs CC)
Number of subjects: 24968

Group type: EXPERIMENTAL
Intervention: Dietary intake of folate/B-vitamins
Number of subjects: 24968
Study: 17337677

Group type: EXPERIMENTAL
Intervention: Hypertonic saline inhalation
Number of subjects: 0
Study: 17344250

Group type: EXPERIMENTAL
Intervention: Disability Living Allowance (DLA) application
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Disability Living Allowance (DLA) monetary award
Number of subjects: 156
Study: 17351381

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine < 0.9 mg/dl
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine 0.9-1.2 mg/dl
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine 1.2-1.6 mg/dl
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine 1.6-2.8 mg/dl
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine >= 2.8 mg/dl
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine (per mg/dl) in LIFE study
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine (per mg/dl) in RENAAL study
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine (per mg/dl) in combined studies
Number of subjects: 2708
Study: 17356709

Group type: EXPERIMENTAL
Intervention: 5,6-dimethylxanthenone-4-acetic acid (DMXAA) 30 mg/kg, i.p.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study: 17360989

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem-cell autograft followed by allograft from an HLA-identical sibling
Number of subjects: 162

Group type: COMPARATOR
Intervention: Tandem autografts (double-autologous-transplant group)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Autograft-allograft group
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Allografting
Number of subjects: 162

Group type: COMPARATOR
Intervention: Double-autologous-transplant group
Number of subjects: 162
Study: 17362525

Group type: EXPERIMENTAL
Intervention: Composite three-marker test (CRP, PCT, Neutrophils)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Composite six-marker test (CRP, PCT, Neutrophils, suPAR, sTREM-1, MIF)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Soluble triggering receptor expressed on myeloid cells (sTREM)-1
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Soluble urokinase-type plasminogen activator (suPAR)
Number of subjects: 151
Study: 17372153

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study: 17377160

Group type: EXPERIMENTAL
Intervention: Severe CNS involvement
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary failure after CNS involvement
Number of subjects: 142

Group type: COMPARATOR
Intervention: CNS involvement alone
Number of subjects: 142
Study: 17379851

Group type: EXPERIMENTAL
Intervention: One deep inspiration
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Five deep inspirations
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Five deep inspirations before methacholine inhalation
Number of subjects: 37
Study: 17392300

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 969
Study: 17392561

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17395103

Group type: EXPERIMENTAL
Intervention: (124)I-cG250 PET
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inactive antibody
Number of subjects: 26
Study: 17418291

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 216
Study: 17425446

Group type: EXPERIMENTAL
Intervention: Pramlintide therapy (120 microg)
Number of subjects: 166
Study: 17426205

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: (18)F-FMT PET
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (lung cancer patients) (18)F-FDG PET
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (lung cancer patients) (18)F-FMT PET
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: (18)F-FMT PET in combination with (18)F-FDG PET
Number of subjects: 24
Study: 17426276

Group type: EXPERIMENTAL
Intervention: High-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation (AHST)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose immunosuppression followed by AHST
Number of subjects: 15
Study: 17431579

Group type: EXPERIMENTAL
Intervention: Common variation in the PPARD gene
Number of subjects: 7495
Study: 17436219

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (highly active antiretroviral therapy)
Number of subjects: 22
Study: 17448368

Group type: EXPERIMENTAL
Intervention: TAXUS Liberté stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAXUS Express stent
Number of subjects: 0
Study: 17448416

Group type: EXPERIMENTAL
Intervention: HF-1 (full set of heart failure discharge instructions and education)
Number of subjects: 33681

Group type: EXPERIMENTAL
Intervention: Performance Improvement (PI) tools
Number of subjects: 33681
Study: 17450048

Group type: EXPERIMENTAL
Intervention: Adjunct services for attrition prevention (ASAP)
Number of subjects: 439
Study: 17460469

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir-based HAART
Number of subjects: 64
Study: 17462825

Group type: EXPERIMENTAL
Intervention: Patients with painful myocardial infarction (MI)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Patients with painless myocardial infarction (MI)
Number of subjects: 92
Study: 17475941

Group type: EXPERIMENTAL
Intervention: Moderate fat reduction diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate reduction diet
Number of subjects: 0
Study: 17488673

Group type: EXPERIMENTAL
Intervention: Bortezomib and dexamethasone
Number of subjects: 12
Study: 17498579

Group type: EXPERIMENTAL
Intervention: BNP quartile Q1 (<430 pg/ml)
Number of subjects: 48629

Group type: EXPERIMENTAL
Intervention: BNP quartile Q2 (430 to 839 pg/ml)
Number of subjects: 48629

Group type: EXPERIMENTAL
Intervention: BNP quartile Q3 (840 to 1,729 pg/ml)
Number of subjects: 48629

Group type: EXPERIMENTAL
Intervention: BNP quartile Q4 (>=1,730 pg/ml)
Number of subjects: 48629
Study: 17502467

Group type: COMPARATOR
Intervention: Testosterone gel (10 g daily, containing 100 mg of testosterone)
Number of subjects: 10
Study: 17503986

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day for 6 weeks, increased to 120 mg/day for the remainder of the 12-week trial as tolerated
Number of subjects: 24
Study: 17504901

Group type: EXPERIMENTAL
Intervention: Ghrelin measurement (hourly between 2300 and 0300 h)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 24-h LH measurement
Number of subjects: 72
Study: 17507719

Group type: EXPERIMENTAL
Intervention: Vascular targeted photodynamic therapy (VTP) with palladium-bacteriopheophorbide
Number of subjects: 25
Study: 17512363

Group type: EXPERIMENTAL
Intervention: CETP tSNP allele +1086A
Number of subjects: 4811

Group type: EXPERIMENTAL
Intervention: CETP tSNP -631AA
Number of subjects: 4811

Group type: EXPERIMENTAL
Intervention: CETP tSNP +2389GA
Number of subjects: 4811

Group type: EXPERIMENTAL
Intervention: Haplotype analysis for LD group B
Number of subjects: 4811

Group type: EXPERIMENTAL
Intervention: Haplotype analysis for LD group A
Number of subjects: 4811

Group type: COMPARATOR
Intervention: TaqIB variant
Number of subjects: 4811

Group type: COMPARATOR
Intervention: tSNP or haplotype associations with myocardial infarction (MI)
Number of subjects: 4811
Study: 17515522

Group type: EXPERIMENTAL
Intervention: Oral bexarotene and extracorporeal photopheresis
Number of subjects: 0
Study: 17519207

Group type: EXPERIMENTAL
Intervention: Topical autologous platelet gel (APG)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional therapy (antibiotic ointment and/or semiocclusive dressing)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical autologous platelet gel (APG) with platelet count > 6 times baseline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: In vitro testing of supplemental APG
Number of subjects: 8
Study: 17530534

Group type: EXPERIMENTAL
Intervention: Two-minute walk test
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Repeated chair rise test
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (Paffenbarger Physical Activity and Exercise Index)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Short-term asthma control
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Correlations between PAEI and performance-based tests
Number of subjects: 258
Study: 17536019

Group type: EXPERIMENTAL
Intervention: Sildenafil (a phosphodiesterase-5 inhibitor)
Number of subjects: 0
Study: 17541048

Group type: EXPERIMENTAL
Intervention: Augmentation pharmacotherapy (bupropion, nortriptyline, or lithium)
Number of subjects: 195

Group type: COMPARATOR
Intervention: No augmentation (control group)
Number of subjects: 195
Study: 17541653

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 60,000 U SC QW during initial dosing phase (IDP)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 80,000 U SC Q3W during extended dosing phase (EDP)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 60,000 U SC QW during IDP
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 80,000 U SC Q3W during EDP
Number of subjects: 115
Study: 17543307

Group type: EXPERIMENTAL
Intervention: EUS/EUS-FNA
Number of subjects: 17

Group type: COMPARATOR
Intervention: CT
Number of subjects: 17

Group type: COMPARATOR
Intervention: US
Number of subjects: 17

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 17
Study: 17544766

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV6/11/16/18 vaccine (n=9087)
Number of subjects: 20583

Group type: EXPERIMENTAL
Intervention: HPV16 vaccine component (n=1204)
Number of subjects: 20583

Group type: COMPARATOR
Intervention: Placebo (n=10,292)
Number of subjects: 20583

Group type: EXPERIMENTAL
Intervention: Overall HPV vaccination (including all types)
Number of subjects: 20583
Study: 17545184

Group type: EXPERIMENTAL
Intervention: Rapid tests for HIV-1
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: Rapid tests for HIV-1 (after excluding weak positive bands)
Number of subjects: 1517
Study: 17557758

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Comparison of Alendronate vs Alfacalcidol
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 201

Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 201
Study: 17558345

Group type: EXPERIMENTAL
Intervention: Simultaneous endotoxin immunoadsorption (IA), IL-6 IA, and C5a IA on 5 consecutive days for 7.5 h each
Number of subjects: 33
Study: 17559726

Group type: EXPERIMENTAL
Intervention: Duloxetine (60-120 mg/day for 10 weeks or 60/120 mg/day for 9 weeks)
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1163
Study: 17560635

Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel lymph node mapping with Tc-99 radiocolloid and blue dye
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blue dye alone
Number of subjects: 20
Study: 17562873

Group type: EXPERIMENTAL
Intervention: Clofarabine (20 mg/m2) + cyclophosphamide (200 mg/m2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clofarabine (10 mg/m2) + cyclophosphamide (200 mg/m2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cyclophosphamide (200 mg/m2) alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clofarabine + cyclophosphamide
Number of subjects: 18
Study: 17563345

Group type: EXPERIMENTAL
Intervention: Cinnamon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17563348

Group type: EXPERIMENTAL
Intervention: Annual 4-day insulin infusions and daily insulin injections
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (closely monitored subjects)
Number of subjects: 298
Study: 17563856

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg once daily and docetaxel 75 mg/m(2) every 3 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Docetaxel alone (as a comparison)
Number of subjects: 33
Study: 17573503

Group type: EXPERIMENTAL
Intervention: Men with COPD
Number of subjects: 396

Group type: COMPARATOR
Intervention: Women with COPD
Number of subjects: 396
Study: 17573882

Group type: EXPERIMENTAL
Intervention: Imiquimod treatment for AIN
Number of subjects: 21
Study: 17577020

Group type: EXPERIMENTAL
Intervention: Oral vorinostat 400 mg daily until disease progression or intolerable toxicity
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral vorinostat 400 mg daily
Number of subjects: 74
Study: 17579184

Group type: EXPERIMENTAL
Intervention: Cy/Flu/DLI
Number of subjects: 15

Group type: COMPARATOR
Intervention: DLI without chemotherapy
Number of subjects: 15
Study: 17579195

Group type: EXPERIMENTAL
Intervention: Growth hormone deficiency (GHD)
Number of subjects: 12
Study: 17585106

Group type: EXPERIMENTAL
Intervention: PEEP >= 10 cm H(2)O and Fi(O(2)) >= 0.5 at Day 1
Number of subjects: 170
Study: 17586030

Group type: EXPERIMENTAL
Intervention: HspE7 (500 microg, 3 monthly subcutaneous vaccinations)
Number of subjects: 58
Study: 17586305

Group type: EXPERIMENTAL
Intervention: Low-dose AAV-GAD gene therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium-dose AAV-GAD gene therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose AAV-GAD gene therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AAV-GAD gene therapy
Number of subjects: 12
Study: 17586747

Group type: EXPERIMENTAL
Intervention: Combined treatment with rosiglitazone and exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17591525

Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU once weekly for 12 weeks and once monthly thereafter for a total of 6 months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ergocalciferol administration
Number of subjects: 66
Study: 17592632

Group type: EXPERIMENTAL
Intervention: Cycloset
Number of subjects: 3095

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3095
Study: 17592924

Group type: EXPERIMENTAL
Intervention: Low endogenous androgen production (measured as serum androgen levels)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Free testosterone levels
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Free testosterone
Number of subjects: 43
Study: 17596485

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17596541

Group type: EXPERIMENTAL
Intervention: 5-azacitidine (5-AZA) at 75 mg/m² subcutaneously daily for 7 days, valproic acid (VPA) orally daily for 7 days (dose-escalated, maximum tolerated dose 50 mg/kg), all-trans retinoic acid (ATRA) at 45 mg/m² orally daily for 5 days starting on day 3.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination of 5-AZA, VPA, and ATRA
Number of subjects: 53
Study: 17597266

Group type: EXPERIMENTAL
Intervention: CJ-50300 smallpox vaccine
Number of subjects: 18
Study: 17601897

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 192

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 192
Study: 17601900

Group type: EXPERIMENTAL
Intervention: Opt-out HIV testing strategy
Number of subjects: 1233
Study: 17607331

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/day
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study: 17609424

Group type: EXPERIMENTAL
Intervention: Genetic modification of antigen-presenting cells (APCs) to augment LMP2 expression.
Number of subjects: 16
Study: 17620582

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17621382

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 240